Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February

Zura Bio Limited (NASDAQ:ZURA) was the target of a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 4,737,248 shares, a growth of 16.2% from the February 12th total of 4,075,644 shares. Based on an average daily volume of 496,325 shares, the days-to-cover ratio is presently 9.5 days. Currently, 9.4% of the shares of the company are short sold. Currently, 9.4% of the shares of the company are short sold. Based on an average daily volume of 496,325 shares, the days-to-cover ratio is presently 9.5 days.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of analyst reports. Leerink Partners upgraded shares of Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Wedbush assumed coverage on shares of Zura Bio in a research note on Monday, February 9th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.60.

Zura Bio Price Performance

Shares of ZURA stock opened at $5.99 on Thursday. The business’s fifty day moving average price is $6.14 and its 200 day moving average price is $4.50. The firm has a market capitalization of $389.47 million, a PE ratio of -9.22 and a beta of 0.18. Zura Bio has a 1-year low of $0.97 and a 1-year high of $7.44.

Insider Buying and Selling at Zura Bio

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was purchased at an average cost of $6.25 per share, with a total value of $12,500,000.00. Following the completion of the acquisition, the insider directly owned 6,552,725 shares in the company, valued at $40,954,531.25. This trade represents a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 14.23% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

Large investors have recently made changes to their positions in the stock. Suvretta Capital Management LLC lifted its stake in shares of Zura Bio by 1.7% in the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after purchasing an additional 94,110 shares during the period. VR Adviser LLC grew its position in Zura Bio by 15.4% during the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after buying an additional 713,899 shares during the period. JPMorgan Chase & Co. increased its holdings in Zura Bio by 78.7% in the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares in the last quarter. Braidwell LP increased its holdings in Zura Bio by 28.6% in the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock valued at $16,665,000 after buying an additional 707,583 shares in the last quarter. Finally, Affinity Asset Advisors LLC lifted its position in shares of Zura Bio by 42.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,813,671 shares of the company’s stock valued at $9,504,000 after acquiring an additional 539,320 shares during the period. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.